Nina Zila

← Back to Hochschule Campus Wien

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. JAK-STAT signaling maintains homeostasis in T cells and macrophages

   2024 · 108 citations

2. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial

   2024 · 54 citations

3. Cutaneous T cell lymphoma atlas reveals malignant TH2 cells supported by a B cell-rich tumor microenvironment

   2024 · 46 citations

4. Octenidine-based hydrogel shows anti-inflammatory and protease-inhibitory capacities in wounded human skin

   2021 · 38 citations

5. Proteomic identification of a marker signature for MAPKi resistance in melanoma

   2019 · 37 citations

6. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

   2023 · 24 citations

7. Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy

   2023 · 22 citations

8. Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

   2018 · 18 citations

9. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma

   2024 · 17 citations

10. Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)

    2025 · 16 citations

11. Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function

    2024 · 11 citations

12. Stiffness-Dependent Lysyl Oxidase Regulation through Hypoxia-Inducing Factor 1 Drives Extracellular Matrix Modifications in Psoriasis

    2024 · 6 citations

13. Novel immune checkpoints beyond PD-1 in advanced melanoma

    2021 · 5 citations

14. Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells

    2022 · 5 citations

15. 794P Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)

    2022 · 4 citations

16. Author Correction: Cutaneous T cell lymphoma atlas reveals malignant TH2 cells supported by a B cell-rich tumor microenvironment

    2024 · 4 citations

17. Extracorporeal photopheresis induces the release of anti-inflammatory fatty acids and oxylipins and suppresses pro-inflammatory sphingosine-1-phosphate

    2025 · 3 citations

18. Cutaneous T cell lymphoma atlas reveals malignant Th2 cells supported by a B cell-rich microenvironment

    2023 · 2 citations

19. zHORSE as an optogenetic zebrafish strain for precise spatiotemporal control over gene expression during development

    2025 · 2 citations

20. Correlation of DNA methylation signatures with response to immune checkpoint inhibitors in metastatic melanoma.

    2023 · 1 citations

21. Supplementary Table S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy

    2024 · 1 citations

22. Combining three‐dimensional histopathology with bread loafing and orientation without artificial coloring

    2022 · 0 citations

23. ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma

    2022 · 0 citations

24. Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

    2023 · 0 citations

25. Supplementary Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

    2023 · 0 citations

← Return to the university profile